Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease

David M G Halpin, Gerard J Criner, Alberto Papi, Dave Singh, Antonio Anzueto, Fernando J Martinez, Alvar A Agusti, Claus F Vogelmeier, David M G Halpin, Gerard J Criner, Alberto Papi, Dave Singh, Antonio Anzueto, Fernando J Martinez, Alvar A Agusti, Claus F Vogelmeier

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has raised many questions about the management of patients with chronic obstructive pulmonary disease (COPD) and whether modifications of their therapy are required. It has raised questions about recognizing and differentiating coronavirus disease (COVID-19) from COPD given the similarity of the symptoms. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee used established methods for literature review to present an overview of the management of patients with COPD during the COVID-19 pandemic. It is unclear whether patients with COPD are at increased risk of becoming infected with SARS-CoV-2. During periods of high community prevalence of COVID-19, spirometry should only be used when it is essential for COPD diagnosis and/or to assess lung function status for interventional procedures or surgery. Patients with COPD should follow basic infection control measures, including social distancing, hand washing, and wearing a mask or face covering. Patients should remain up to date with appropriate vaccinations, particularly annual influenza vaccination. Although data are limited, inhaled corticosteroids, long-acting bronchodilators, roflumilast, or chronic macrolides should continue to be used as indicated for stable COPD management. Systemic steroids and antibiotics should be used in COPD exacerbations according to the usual indications. Differentiating symptoms of COVID-19 infection from chronic underlying symptoms or those of an acute COPD exacerbation may be challenging. If there is suspicion for COVID-19, testing for SARS-CoV-2 should be considered. Patients who developed moderate-to-severe COVID-19, including hospitalization and pneumonia, should be treated with evolving pharmacotherapeutic approaches as appropriate, including remdesivir, dexamethasone, and anticoagulation. Managing acute respiratory failure should include appropriate oxygen supplementation, prone positioning, noninvasive ventilation, and protective lung strategy in patients with COPD and severe acute respiratory distress syndrome. Patients who developed asymptomatic or mild COVID-19 should be followed with the usual COPD protocols. Patients who developed moderate or worse COVID-19 should be monitored more frequently and accurately than the usual patients with COPD, with particular attention to the need for oxygen therapy.

Keywords: COVID-19; chronic obstructive pulmonary disease; diagnosis; treatment.

Figures

Figure 1.
Figure 1.
Chronic obstructive pulmonary disease and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: clinical features, abnormal investigations, and possible interventions at different stages of the disease. ARDS = acute respiratory distress syndrome; BNP = brain natriuretic peptide; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease; CRP = C-reactive protein; CT = computed tomography; CXR = chest radiograph; HFNT = high-flow nasal therapy; IMV = invasive mechanical ventilation; LDH = lactate dehydrogenase; NIV = noninvasive ventilation; PCT = procalcitonin; PFT = pulmonary function tests; PR = pulmonary rehabilitation; SIRS = systemic inflammatory response syndrome; SOB = shortness of breath; SpO2 = peripheral oxygen saturation; VTE = venous thromboembolism.

References

    1. Mahase E. Covid-19: increased demand for steroid inhalers causes “distressing” shortages. BMJ. 2020;369:m1393.
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280, e8.
    1. Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2020;202:8–10.
    1. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55:2000688.
    1. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19–related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202:83–90.
    1. Streeck H, Schulte B, Kuemmerer B, Richter E, Hoeller T, Fuhrmann C.Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event [preprint]medRxiv2020[accessed 2019 Mar 12]. Available from:
    1. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54-75 years [preprint]medRxiv2020[accessed 2019 Mar 12]. Available from:
    1. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20:1034–1042.
    1. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106:1503–1511.
    1. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8:436–438.
    1. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J. 2020;56:2002108.
    1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
    1. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020;167:105941.
    1. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180:1345–1355.
    1. Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis Diabetes Obes Metab[online ahead of print] 23 Jun 202010.1111/dom.14124
    1. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
    1. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. STOP-COVID Investigators Factors associated with death in critically ill patients with coronavirus disease 2019 in the US JAMA Intern Med[online ahead of print] 15 Jul 202010.1001/jamainternmed.2020.3596
    1. Elbeddini A, Tayefehchamani Y.Amid COVID-19 pandemic: challenges with access to care for COPD patients Res Social Adm Pharm[online ahead of print] 2 Jun 202010.1016/j.sapharm.2020.06.002
    1. Press VG, Gershon AS, Sciurba FC, Blagev DP. Concerns about coronavirus disease-related collateral damage for patients with COPD. Chest. 2020;158:866–868.
    1. Berghaus TM, Karschnia P, Haberl S, Schwaiblmair M. Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic. Respir Med. 2020;10:106120.
    1. Chan KPF, Ma TF, Kwok WC, Leung JKC, Chiang KY, Ho JCM, et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020;171:106085.
    1. World Health Organization Smoking and COVID-19: scientific brief World Health Organization; 2020[created 2020 June 30; accessed 2020 Oct 25]. Available from:
    1. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296:E115–E117.
    1. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak J Med Virol[online ahead of print] 12 Jun 202010.1002/jmv.26163
    1. Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, et al. COCOREC study group. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound? J Infect. 2020;81:816–846.
    1. Mammen MJ, Sethi S. COPD and the microbiome. Respirology. 2016;21:590–599.
    1. Khatiwada S, Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications. Hum Microb J. 2020;17:100073.
    1. European Respiratory Society Recommendation from ERS Group 9.1 (Respiratory function technologists/Scientists): lung function testing during COVID-19 pandemic and beyond European Respiratory Society; 2020[accessed 2020 Oct 25]. Available from:
    1. McCormack MC, Kaminsky DAAmerican Thoracic Society Pulmonary function laboratories: advice regarding COVID-19 American Thoracic Society; 2020[accessed 2020 Oct 25]. Available from:
    1. Martinez FJ, Mannino D, Leidy NK, Malley KG, Bacci ED, Barr RG, et al. High-Risk-COPD Screening Study Group. A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:748–756.
    1. Jithoo A, Enright PL, Burney P, Buist AS, Bateman ED, Tan WC, et al. BOLD Collaborative Research Group. Case-finding options for COPD: results from the burden of obstructive lung disease study. Eur Respir J. 2013;41:548–555.
    1. Mahboub B, Alzaabi A, Soriano JB, Salameh L, Mutairi YA, Yusufali AA, et al. Case-finding of chronic obstructive pulmonary disease with questionnaire, peak flow measurements and spirometry: a cross-sectional study. BMC Res Notes. 2014;7:241.
    1. Perez-Padilla R, Vollmer WM, Vázquez-García JC, Enright PL, Menezes AM, Buist AS BOLD and PLATINO Study Groups. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis. 2009;13:387–393.
    1. Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poor. Chest. 2006;130:1454–1461.
    1. Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, Bumroongkit C, Deesomchok A, et al. Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand. Int J Chron Obstruct Pulmon Dis. 2015;10:1213–1218.
    1. Llewellin P, Sawyer G, Lewis S, Cheng S, Weatherall M, Fitzharris P, et al. The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology. 2002;7:333–337.
    1. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ. 2003;327:653–654.
    1. Carpenter DM, Jurdi R, Roberts CA, Hernandez M, Horne R, Chan A. A review of portable electronic spirometers: implications for asthma self-management. Curr Allergy Asthma Rep. 2018;18:53.
    1. Ramos Hernández C, Núñez Fernández M, Pallares Sanmartín A, Mouronte Roibas C, Cerdeira Domínguez L, Botana Rial MI, et al. Validation of the portable air-smart spirometer. PLoS One. 2018;13:e0192789.
    1. Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, et al. American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 infection. J Bronchology Interv Pulmonol. 2020;27:e52–e54.
    1. Wahidi MM, Shojaee S, Lamb CR, Ost D, Maldonado F, Eapen G, et al. The use of bronchoscopy during the coronavirus disease 2019 pandemic: CHEST/AABIP guideline and expert panel report. Chest. 2020;158:1268–1281.
    1. Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology. 2020;296:E72–E78.
    1. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the fleischner society. Radiology. 2020;296:172–180.
    1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
    1. Kulkarni S, Down B, Jha S. Point-of-care lung ultrasound in intensive care during the COVID-19 pandemic. Clin Radiol. 2020;75:710, e1–710, e4.
    1. Inui S, Fujikawa A, Jitsu M, Kunishima N, Watanabe S, Suzuki Y, et al. Findings in cases from the cruise ship “diamond princess” with coronavirus disease 2019 (COVID-19) Radiol Cardiothorac Imaging. 2020;2:e200110.
    1. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020;215:87–93.
    1. Wu F, Zhou Y, Wang Z, Xie M, Shi Z, Tang Z, et al. Medical Treatment Expert Group for COPD and COVID-19. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study. J Thorac Dis. 2020;12:1811–1823.
    1. Tittaferrante S, Gupta R, Kim V Temple University COVID-19 Research Group. Thoracic computed tomography features of coronavirus disease 2019 patients with emphysema. Chronic Obstr Pulm Dis (Miami) 2020;7:290–296.
    1. Mossa-Basha M, Meltzer CC, Kim DC, Tuite MJ, Kolli KP, Tan BS. Radiology department preparedness for COVID-19: radiology scientific expert review panel. Radiology. 2020;296:E106–E112.
    1. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116–1120.
    1. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–2371.
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
    1. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.
    1. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18:1743–1746.
    1. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–1098.
    1. Esposito S, Principi N, Leung CC, Migliori GB. Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. Eur Respir J. 2020;55:2001260.
    1. Long Y, Hu T, Liu L, Chen R, Guo Q, Yang L, et al. Effectiveness of N95 respirators versus surgical masks against influenza: a systematic review and meta-analysis. J Evid Based Med. 2020;13:93–101.
    1. American College of Chest Physicians, American Lung Association, American Thoracic Society, COPD Foundation Joint statement on importance of patients with chronic lung disease wearing facial coverings during COVID-19 pandemic American College of Chest Physicians; 2020[created 2020 July 17; accessed 2020 Oct 25]. Available from:
    1. Kyung SY, Kim Y, Hwang H, Park JW, Jeong SH. Risks of N95 face mask use in subjects with COPD. Respir Care. 2020;65:658–664.
    1. Samannan R, Holt G, Calderon-Candelario R, Mirsaeidi M, Campos M.Effect of face masks on gas exchange in healthy persons and patients with COPD Ann Am Thorac Soc[online ahead of print] 2 Oct 202010.1513/AnnalsATS.202007-812RL
    1. Perencevich EN, Diekema DJ, Edmond MB. Moving personal protective equipment into the community: face shields and containment of COVID-19. JAMA. 2020;323:2252–2253.
    1. CDC Considerations for wearing masks: help slow the spread of COVID-19 CDC; 2020[accessed 2020 Oct 25]. Available from:
    1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease; 2020[updated 2020 Nov 4; accessed 2020 Oct 25]. Available from:
    1. Ergan B, Akgun M, Pacilli AMG, Nava S. Should I stay or should I go? COPD and air travel. Eur Respir Rev. 2018;27:180030.
    1. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012;7:e35797.
    1. Neufeld Z, Khataee H, Czirok A. Targeted adaptive isolation strategy for COVID-19 pandemic. Infect Dis Model. 2020;5:357–361.
    1. Butler N, Tulloch OSSHAP Considerations and principles for shielding people at high risk of severe outcomes from COVID-19 Institute of Developed Studies; 2020[created 2020 May 7; accessed 2020 Oct 25]. Available from:
    1. Tal-Singer R, Crapo JD. COPD at the time of COVID-19: a COPD foundation perspective. Chronic Obstr Pulm Dis (Miami) 2020;7:73–75.
    1. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993–998.
    1. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
    1. Carfì A, Bernabei R, Landi F Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605.
    1. Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9:2229.
    1. Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, Xepapadaki P, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy. 2009;39:1700–1710.
    1. Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep. 2014;4:7176.
    1. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58:155–168.
    1. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55:2001009.
    1. Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis [preprint] MedRxiv 2020[created 2020 June 20; accessed 2020 Jun 20] Available from:
    1. Singh D, Halpin DMG. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? Lancet Respir Med. 2020;8:1065–1066.
    1. O’Neil CA, Li J, Leavey A, Wang Y, Hink M, Wallace M, et al. Centers for Disease Control and Prevention Epicenters Program. Characterization of aerosols generated during patient care activities. Clin Infect Dis. 2017;65:1335–1341.
    1. Simonds AK, Hanak A, Chatwin M, Morrell M, Hall A, Parker KH, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess. 2010;14:131–172.
    1. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–1567.
    1. Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:472–476.
    1. Tashkin DP, Barjaktarevic IZ. Nebulized treatments and the possible risk of coronavirus transmission: where is the evidence? Chronic Obstr Pulm Dis (Miami) 2020;7:136–138.
    1. Respiratory Care Committee of Chinese Thoracic Society. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia [in Chinese] Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:288–296.
    1. Salisbury H. Helen Salisbury: how will we run flu clinics in a pandemic? BMJ. 2020;370:m3033.
    1. Demeyer H, Louvaris Z, Frei A, Rabinovich RA, de Jong C, Gimeno-Santos E, et al. Mr Papp PROactive study group and the PROactive consortium. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72:415–423.
    1. American Thoracic Society Assembly on pulmonary rehabilitation: guidance for re-opening-opening pulmonary rehabilitation programs American Thoracic Society; 2020[accessed 2020 Oct 25]. Available from:
    1. Nield M, Hoo GW. Real-time telehealth for COPD self-management using Skype™. COPD. 2012;9:611–619.
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members Remdesivir for the treatment of covid-19 - final report N Engl J Med[online ahead of print] 8 Oct 202010.1056/NEJMoa2007764
    1. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. RECOVERY Collaborative Group Dexamethasone in hospitalized patients with covid-19 - preliminary report N Engl J Med[online ahead of print] 17 Jul 202010.1056/NEJMoa2021436
    1. Muhammad S, Long X, Salman M. COVID-19 pandemic and environmental pollution: a blessing in disguise? Sci Total Environ. 2020;728:138820.
    1. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10:158–174.
    1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383:120–128.
    1. Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477:359–372.
    1. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35:157–163.
    1. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996.
    1. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis BMJ Evid Based Med[online ahead of print] 15 Sep 202010.1136/bmjebm-2020-111536
    1. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683–684.
    1. Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936.
    1. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–767.
    1. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309.
    1. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500.
    1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475.
    1. World Health Organization Clinical management of COVID-19: interim guidance World Health Organization; 2020[created 2020 May 27; accessed 2020 Oct 25]. Available from:
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943.
    1. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–1341.
    1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing Clin Infect Dis[Online ahead of print] 2 May 202010.1093/cid/ciaa530
    1. Verroken A, Scohy A, Gérard L, Wittebole X, Collienne C, Laterre PF. Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis. Crit Care. 2020;24:410.
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
    1. Jiang DH, McCoy RG. Planning for the post-COVID syndrome: how payers can mitigate long-term complications of the pandemic. J Gen Intern Med. 2020;35:3036–3039.
    1. Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern Pathology. 2020;33:2156–2168.
    1. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020;24:154.
    1. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:1299–1300.
    1. Panwar R, Madotto F, Laffey JG, Van Haren FMP. Compliance phenotypes in early acute respiratory distress syndrome before the COVID-19 pandemic. Am J Respir Crit Care Med. 2020;202:1244–1252.
    1. Brault C, Zerbib Y, Kontar L, Fouquet U, Carpentier M, Metzelard M, et al. COVID-19– versus non-COVID-19–related acute respiratory distress syndrome: differences and similarities. Am J Respir Crit Care Med. 2020;202:1301–1304.
    1. Grieco DL, Bongiovanni F, Chen L, Menga LS, Cutuli SL, Pintaudi G, et al. Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies. Crit Care. 2020;24:529.
    1. Lechowicz K, Drożdżal S, Machaj F, Rosik J, Szostak B, Zegan-Barańska M, et al. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med. 2020;9:1917.
    1. Remmelink M, De Mendonça R, D’Haene N, De Clercq S, Verocq C, Lebrun L, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care. 2020;24:495.
    1. Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy aging. Aging Clin Exp Res. 2020;32:1189–1194.
    1. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45:100618.
    1. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590–592.
    1. Dobesh PP, Trujillo TC.Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19 Pharmacotherapy[online ahead of print] 1 Oct 202010.1002/phar.2465
    1. Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res. 2003;112:203–207.
    1. Kim V, Goel N, Gangar J, Zhao H, Ciccolella DE, Silverman EK, et al. COPD Gene Investigators. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis (Miami) 2014;1:239–249.
    1. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:122–124.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242.
    1. Qiu H, Tong Z, Ma P, Hu M, Peng Z, Wu W, et al. China Critical Care Clinical Trials Group. Intensive care during the coronavirus epidemic. Intensive Care Med. 2020;46:576–578.
    1. Johns Hopkins University & Medicine. Johns Hopkins Coronavirus Resource Center Johns Hopkins University & Medicine; 2020[accessed 2020 Oct 25]. Available from:
    1. Schünemann HJ, Khabsa J, Solo K, Khamis AM, Brignardello-Petersen R, El-Harakeh A, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med. 2020;173:204–216.
    1. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574–1581.
    1. Ñamendys-Silva SA. Respiratory support for patients with COVID-19 infection. Lancet Respir Med. 2020;8:e18.
    1. Kluge S, Janssens U, Welte T, Weber-Carstens S, Marx G, Karagiannidis C.German recommendations for critically ill patients with COVID-19 Med Klin Intensivmed Notf Med[online ahead of print] 14 Apr 202010.1007/s00063-020-00689-w
    1. Cheung JC, Ho LT, Cheng JV, Cham EYK, Lam KN. Staff safety during emergency airway management for COVID-19 in Hong Kong. Lancet Respir Med. 2020;8:e19.
    1. Crimi C, Noto A, Cortegiani A, Impellizzeri P, Elliott M, Ambrosino N, et al. Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections Minerva Anestesiol[online ahead of print] 5 Aug 202010.23736/S0375-9393.20.14785-0
    1. Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. BMJ Open Respir Res. 2020;7:e000650.
    1. Demoule A, Vieillard Baron A, Darmon M, Beurton A, Géri G, Voiriot G, et al. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020;202:1039–1042.
    1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185–2196.
    1. Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation: a systematic review and meta-analysis. Am J Emerg Med. 2018;36:226–233.
    1. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Crit Care Med. 2020;48:e440–e469.
    1. Telias I, Katira BH, Brochard L. Is the prone position helpful during spontaneous breathing in patients with COVID-19? JAMA. 2020;323:2265–2267.
    1. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;369:2126–2136.
    1. Berlin DA, Gulick RM, Martinez FJ.Severe covid-19 N Engl J Med[online ahead of print] 15 May 202010.1056/NEJMcp2009575
    1. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med. 2020;8:816–821.
    1. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. LUNG SAFE Investigators; ESICM Trials Group. Noninvasive ventilation of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Am J Respir Crit Care Med. 2017;195:67–77.
    1. Ma X, Liang M, Ding M, Liu W, Ma H, Zhou X, et al. Extracorporeal membrane oxygenation (ECMO) in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia and acute respiratory distress syndrome (ARDS) Med Sci Monit. 2020;26:e925364.
    1. Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, et al. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. ASAIO J. 2020;66:472–474.
    1. MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. 2020;323:1245–1246.
    1. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8:518–526.
    1. Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, et al. ELSO Guideline Working Group* Extracorporeal life support organization COVID-19 interim guidelines ASAIO J[online ahead of print] 29 Apr 202010.1097/MAT.0000000000001193
    1. Hamele M, Neumayer K, Sweney J, Poss WB. Always ready, always prepared-preparing for the next pandemic. Transl Pediatr. 2018;7:344–355.
    1. Zochios V, Brodie D, Charlesworth M, Parhar KK. Delivering extracorporeal membrane oxygenation for patients with COVID-19: what, who, when and how? Anaesthesia. 2020;75:997–1001.
    1. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020;55:2000892.
    1. Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010;5:e10717.
    1. Hautmann H, Gamarra F, Pfeifer KJ, Huber RM. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. Chest. 2001;120:43–49.
    1. Pfeifer M, Ewig S, Voshaar T, Randerath WJ, Bauer T, Geiseler J, et al. Position paper for the state-of-the-art application of respiratory support in patients with COVID-19. Respiration. 2020;99:521–542.
    1. Shaw KM, Lang AL, Lozano R, Szabo M, Smith S, Wang J. Intensive care unit isolation hood decreases risk of aerosolization during noninvasive ventilation with COVID-19. Can J Anaesth. 2020;67:1481–1483.
    1. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82:53–59.
    1. Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders’ conference. Crit Care Med. 2012;40:502–509.
    1. Needham DM, Feldman DR, Kho ME. The functional costs of ICU survivorship: collaborating to improve post-ICU disability. Am J Respir Crit Care Med. 2011;183:962–964.
    1. Herridge MS, Chu LM, Matte A, Tomlinson G, Chan L, Thomas C, et al. RECOVER Program Investigators (Phase 1: towards RECOVER); Canadian Critical Care Trials Group. The RECOVER program: disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. Am J Respir Crit Care Med. 2016;194:831–844.
    1. Griffith DM, Salisbury LG, Lee RJ, Lone N, Merriweather JL, Walsh TS RECOVER Investigators. Determinants of health-related quality of life after ICU: importance of patient demographics, previous comorbidity, and severity of illness. Crit Care Med. 2018;46:594–601.
    1. Holm SE, Mu K. Discharge planning for the elderly in acute care: the perceptions of experienced occupational therapists. Phys Occup Ther Geriatr. 2012;30:214–228.
    1. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated international task force. Eur Respir J. 2020;10:2002197.
    1. Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–409.
    1. Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27:342–349.
    1. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate covid-19. N Engl J Med. 2020;383:1757–1766.
    1. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15:e0233147.
    1. Hosey MM, Needham DM. Survivorship after COVID-19 ICU stay. Nat Rev Dis Primers. 2020;6:60.
    1. Lamas D. Chronic critical illness. N Engl J Med. 2014;370:175–177.
    1. Tracy CS, Bell SH, Nickell LA, Charles J, Upshur RE. The IMPACT clinic: innovative model of interprofessional primary care for elderly patients with complex health care needs. Can Fam Physician. 2013;59:e148–e155.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren